vaccine

Latest stories

  • in Health care

    SII in talks on fill finishing Oxford University R21 malaria vaccine in Ghana: Expert

    by

    Bengaluru: Vaccine manufacturer Serum Institute of India is holding talks on fill-finishing Oxford University‘s R21 malaria vaccine in Ghana, which approved the shot this month, a Ghanaian vaccine expert said on Thursday. Fill-finishing is one of the final stages of drug manufacturing and packaging. The vaccine’s approval by Ghana and Nigeria was unusual because final-stage […] More

  • in Health care

    Merck-Moderna vaccine helps keep patients free from skin cancer

    by

    An experimental mRNA cancer vaccine developed by Moderna Inc and Merck & Co cut the risk of death or recurrence of the most deadly skin cancer by 44 percent compared with Merck’s immunotherapy Keytruda alone, U.S. researchers reported at a medical meeting on Sunday. The findings suggest that adding a personalized cancer vaccine based on […] More

  • in Health care

    Revise Phase I/II CT protocol: CDSCO panel tells Serum Institute of India on Dengue Tetravalent Vaccine

    Revise Phase I/II CT protocol: CDSCO panel tells Serum Institute of India on Dengue Tetravalent Vaccine

    by

    New Delhi: Regarding the Phase I/II clinical trial of Dengue Tetravalent Vaccine (Live, Attenuated), the Subject Expert Committee (SEC) functional under Central Drug Standard Control Organization (CDSCO) has opined the vaccine major Serum Institute of India to revise the Phase I/II clinical trial protocol. This came after the firm presented its proposal to conduct of […] More

  • in Health care

    Moderna, Merck cancer vaccine plus Keytruda delays skin cancer return

    Moderna, Merck cancer vaccine plus Keytruda delays skin cancer return

    by

    New Delhi: An experimental mRNA cancer vaccine developed by Moderna Inc and Merck & Co cut the risk of death or recurrence of the most deadly skin cancer by 44 percent compared with Merck‘s immunotherapy Keytruda alone, U.S. researchers reported at a medical meeting on Sunday. The findings suggest that adding a personalized cancer vaccine […] More

  • in Health care

    Revise Phase IV CT Protocol: CDSCO panel tells Zydus Lifesciences on Typhoid Vi Conjugate Vaccine with Yellow Fever Vaccine

    Revise Phase IV CT Protocol: CDSCO panel tells Zydus Lifesciences on Typhoid Vi Conjugate Vaccine with Yellow Fever Vaccine

    by

    New Delhi: In response to the drug major Zydus Life Sciences’ proposal to conduct Phase IV clinical for Typhoid Vi Conjugate Vaccine I.P.(TCV) with Yellow Fever Vaccine(YFV), the Subject Expert Committee (SEC) functional under Central Drug Standard Control Organization (CDSCO) has opined the firm to revise the Phase IV clinical trial protocol. This came after […] More

  • in Health care

    University of Oxford Malaria vaccine gets regulatory clearance for use in Ghana

    University of Oxford Malaria vaccine gets regulatory clearance for use in Ghana

    by

    London: The R21/Matrix-M malaria vaccine, developed by the University of Oxford, leveraging an adjuvant technology from Novavax, and manufactured and scaled up by the Serum Institute of India Pvt Ltd (SIIPL), has been granted full national licensure for use in Ghana by the country’s Food and Drugs Authority (FDA Ghana). This marks the first regulatory […] More

  • in Health care

    Moderna fends off Arbutus appeal in COVID vaccine patent fight

    Moderna fends off Arbutus appeal in COVID vaccine patent fight

    by

    US:  U.S. appeals court handed Moderna Inc a win on Tuesday, affirming a decision to cancel an Arbutus Biopharma Corp patent related to the companies’ legal fight over Moderna’s blockbuster COVID-19 vaccines. The U.S. Court of Appeals for the Federal Circuit upheld a U.S. Patent and Trademark Office tribunal’s ruling that the patent for Arbutus’ lipid […] More

  • in Health care

    Pfizer RSV vaccine 82 percent effective in severe infection in infants: Data

    Pfizer RSV vaccine 82 percent effective in severe infection in infants: Data

    by

    New Delhi: Pfizer Inc’s experimental respiratory syncytial virus (RSV) vaccine was 82 percent effective in preventing severe infections in infants when given to expecting mothers in the second half of their pregnancy, according to trial details published on Wednesday that confirm preliminary data from the study. Final data from the study that was halted early […] More

  • in Health care

    Pfizer, BioNTech dragged to Court over COVID vaccine patent infringement once again

    by

    US: Arbutus Biopharma on Tuesday sued U.S. drugmaker Pfizer Inc. and its German partner BioNTech SE in a New Jersey district court, claiming their mRNA COVID-19 vaccines infringe five of Arbutus’ patents. Arbutus, along with its licensee Genevant Sciences, is seeking damages, including reasonable royalties, over the use of lipid nanoparticle (LNP) delivery technology in Pfizer/BioNTech vaccines […] More

  • in Health care

    GSK declares positive pivotal phase III data for 5-in-1 Meningococcal ABCWY vaccine

    by

    London: GSK plc has announced positive headline results from the phase III trial (NCT04502693) evaluating the safety, tolerability, and immunogenicity of its MenABCWY combination vaccine candidate, administered as two doses given six months apart in healthy individuals aged 10-25 years. GSK’s MenABCWY vaccine candidate combines the antigenic components of its licensed meningococcal vaccines, Bexsero (MenB) […] More